Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
49
SNDX Quote, Financials, Valuation and Earnings
Last price:
$22.03
Seasonality move
:
0.6%
Day range:
$21.00 - $22.68
52-week range:
$8.58 - $22.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.11x
P/B ratio:
29.77x
Volume:
1.7M
Avg. volume:
1.2M
1-year change:
41.56%
Market cap:
$1.9B
Revenue:
$172.4M
EPS (TTM):
-$3.30
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SNDX
Syndax Pharmaceuticals, Inc.
|
$64.7M | -$0.58 | 266.09% | -42.33% | $38.09 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.80 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835M | $0.56 | 4.63% | 9.11% | $88.39 |
|
IMNN
Imunon, Inc.
|
-- | -$1.82 | -- | -269.06% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SNDX
Syndax Pharmaceuticals, Inc.
|
$22.14 | $38.09 | $1.9B | -- | $0.00 | 0% | 11.11x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.81 | $31.80 | $3.9B | 9.97x | $0.00 | 0% | 3.61x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$325.07 | $457.00 | $43.1B | 144.02x | $0.00 | 0% | 11.68x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$59.74 | $88.39 | $11.5B | 33.53x | $0.00 | 0% | 3.58x |
|
IMNN
Imunon, Inc.
|
$3.29 | $21.50 | $7M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$6.01 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SNDX
Syndax Pharmaceuticals, Inc.
|
84.24% | -0.909 | 18.92% | 3.60x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 0.880 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.55% | -0.788 | 5.63% | 3.25x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.412 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
24.02% | -2.483 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SNDX
Syndax Pharmaceuticals, Inc.
|
$66M | -$62.5M | -55.56% | -169.76% | -91.01% | -$69.5M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$614.5M | $99.8M | 5.33% | 5.89% | 11.16% | $56.6M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Syndax Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns SNDX or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -98.96% compared to Syndax Pharmaceuticals, Inc.'s net margin of 96.33%. Syndax Pharmaceuticals, Inc.'s return on equity of -169.76% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital SNDXSyndax Pharmaceuticals, Inc.96.06% -$0.78 $410.1M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About SNDX or ACAD?
Syndax Pharmaceuticals, Inc. has a consensus price target of $38.09, signalling upside risk potential of 72.05%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.80 which suggests that it could grow by 39.41%. Given that Syndax Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Syndax Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNDXSyndax Pharmaceuticals, Inc.10 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is SNDX or ACAD More Risky?
Syndax Pharmaceuticals, Inc. has a beta of 0.425, which suggesting that the stock is 57.466% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock SNDX or ACAD?
Syndax Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNDX or ACAD?
Syndax Pharmaceuticals, Inc. quarterly revenues are $68.7M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Syndax Pharmaceuticals, Inc.'s net income of -$68M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Syndax Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals, Inc. is 11.11x versus 3.61x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNDXSyndax Pharmaceuticals, Inc.11.11x -- $68.7M -$68M ACADACADIA Pharmaceuticals, Inc.3.61x 9.97x $284M $273.6M
-
Which has Higher Returns SNDX or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -98.96% compared to Syndax Pharmaceuticals, Inc.'s net margin of 16.99%. Syndax Pharmaceuticals, Inc.'s return on equity of -169.76% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital SNDXSyndax Pharmaceuticals, Inc.96.06% -$0.78 $410.1M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About SNDX or ALNY?
Syndax Pharmaceuticals, Inc. has a consensus price target of $38.09, signalling upside risk potential of 72.05%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 40.59%. Given that Syndax Pharmaceuticals, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Syndax Pharmaceuticals, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNDXSyndax Pharmaceuticals, Inc.10 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is SNDX or ALNY More Risky?
Syndax Pharmaceuticals, Inc. has a beta of 0.425, which suggesting that the stock is 57.466% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.
-
Which is a Better Dividend Stock SNDX or ALNY?
Syndax Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNDX or ALNY?
Syndax Pharmaceuticals, Inc. quarterly revenues are $68.7M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Syndax Pharmaceuticals, Inc.'s net income of -$68M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Syndax Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 144.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals, Inc. is 11.11x versus 11.68x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNDXSyndax Pharmaceuticals, Inc.11.11x -- $68.7M -$68M ALNYAlnylam Pharmaceuticals, Inc.11.68x 144.02x $1.1B $186.4M
-
Which has Higher Returns SNDX or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -98.96% compared to Syndax Pharmaceuticals, Inc.'s net margin of -5.2%. Syndax Pharmaceuticals, Inc.'s return on equity of -169.76% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital SNDXSyndax Pharmaceuticals, Inc.96.06% -$0.78 $410.1M BMRNBioMarin Pharmaceutical, Inc.68.65% -$0.24 $6.7B -
What do Analysts Say About SNDX or BMRN?
Syndax Pharmaceuticals, Inc. has a consensus price target of $38.09, signalling upside risk potential of 72.05%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.39 which suggests that it could grow by 47.96%. Given that Syndax Pharmaceuticals, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Syndax Pharmaceuticals, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNDXSyndax Pharmaceuticals, Inc.10 0 0 BMRNBioMarin Pharmaceutical, Inc.14 5 0 -
Is SNDX or BMRN More Risky?
Syndax Pharmaceuticals, Inc. has a beta of 0.425, which suggesting that the stock is 57.466% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.248, suggesting its less volatile than the S&P 500 by 75.229%.
-
Which is a Better Dividend Stock SNDX or BMRN?
Syndax Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNDX or BMRN?
Syndax Pharmaceuticals, Inc. quarterly revenues are $68.7M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $895M. Syndax Pharmaceuticals, Inc.'s net income of -$68M is lower than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Syndax Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 33.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals, Inc. is 11.11x versus 3.58x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNDXSyndax Pharmaceuticals, Inc.11.11x -- $68.7M -$68M BMRNBioMarin Pharmaceutical, Inc.3.58x 33.53x $895M -$46.6M
-
Which has Higher Returns SNDX or IMNN?
Imunon, Inc. has a net margin of -98.96% compared to Syndax Pharmaceuticals, Inc.'s net margin of --. Syndax Pharmaceuticals, Inc.'s return on equity of -169.76% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital SNDXSyndax Pharmaceuticals, Inc.96.06% -$0.78 $410.1M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About SNDX or IMNN?
Syndax Pharmaceuticals, Inc. has a consensus price target of $38.09, signalling upside risk potential of 72.05%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 553.5%. Given that Imunon, Inc. has higher upside potential than Syndax Pharmaceuticals, Inc., analysts believe Imunon, Inc. is more attractive than Syndax Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNDXSyndax Pharmaceuticals, Inc.10 0 0 IMNNImunon, Inc.3 1 0 -
Is SNDX or IMNN More Risky?
Syndax Pharmaceuticals, Inc. has a beta of 0.425, which suggesting that the stock is 57.466% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.057, suggesting its more volatile than the S&P 500 by 105.729%.
-
Which is a Better Dividend Stock SNDX or IMNN?
Syndax Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNDX or IMNN?
Syndax Pharmaceuticals, Inc. quarterly revenues are $68.7M, which are larger than Imunon, Inc. quarterly revenues of --. Syndax Pharmaceuticals, Inc.'s net income of -$68M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, Syndax Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals, Inc. is 11.11x versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNDXSyndax Pharmaceuticals, Inc.11.11x -- $68.7M -$68M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns SNDX or SVRA?
Savara, Inc. has a net margin of -98.96% compared to Syndax Pharmaceuticals, Inc.'s net margin of --. Syndax Pharmaceuticals, Inc.'s return on equity of -169.76% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital SNDXSyndax Pharmaceuticals, Inc.96.06% -$0.78 $410.1M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About SNDX or SVRA?
Syndax Pharmaceuticals, Inc. has a consensus price target of $38.09, signalling upside risk potential of 72.05%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 79.91%. Given that Savara, Inc. has higher upside potential than Syndax Pharmaceuticals, Inc., analysts believe Savara, Inc. is more attractive than Syndax Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNDXSyndax Pharmaceuticals, Inc.10 0 0 SVRASavara, Inc.6 0 0 -
Is SNDX or SVRA More Risky?
Syndax Pharmaceuticals, Inc. has a beta of 0.425, which suggesting that the stock is 57.466% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.931%.
-
Which is a Better Dividend Stock SNDX or SVRA?
Syndax Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNDX or SVRA?
Syndax Pharmaceuticals, Inc. quarterly revenues are $68.7M, which are larger than Savara, Inc. quarterly revenues of --. Syndax Pharmaceuticals, Inc.'s net income of -$68M is lower than Savara, Inc.'s net income of -$29.6M. Notably, Syndax Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals, Inc. is 11.11x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNDXSyndax Pharmaceuticals, Inc.11.11x -- $68.7M -$68M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is down 9.65% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is down 6.93% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is down 0.87% over the past day.
